Report: Nearly 80% of U.S. prescriptions are for generic drugs
DUBLIN — The United States is the biggest generic drugs market in the world, with nearly 80% of prescriptions in American written for generics, according to Research and Markets’ “Analyzing the Generic Drugs Sector of the U.S. Pharmaceutical Industry 2017.”
The report also includes a section called “Promoting Generic Drug Competition in the US Market,” which covers topics such as issues with the FDA Approval Process, the role of the Orange Book, the positive and negative outcomes of the Hatch Waxman Act, the manipulation of this act, promoting methods for generic drug availability, amongst other points of discussion.
Also includes are strategies for survival employed by branded manufacturers, the role of generic drugs in lowering US drug re-importation, a case study on generic antidepressants, the approval of the generic version of GSK's drug Coreg, the introduction of Bill S.438, and the substantial move by Blue Cross in major changes to its drug plans, are discussed and analyzed in this report.
In addition, covered in the report is an analysis of major industry players, such as Teva, Mylan, Sandoz and Sanofi.
For more information about the report, click here.
NCPA partners with PRS Pharmacy Services on pharmacy broker offering
ALEXANDRIA, Va. — The National Community Pharmacists Association on Thursday announced a new strategic partnership with the PRS Pharmacy Services around an exclusive pharmacy Seller/Buyer Offering Plan for the 22,000 independent community pharmacies NCPA represents.
"What sets PRS apart from the typical 'broker' is their ability to handle every aspect of the preparation, sale and post-sale transition process," noted Douglas Hoey, CEO NCPA. "PRS works with independents in all 50 states and, most importantly, PRS will prioritize making sure independents stay independent, which is good for NCPA and all independent pharmacy owners."
The Seller/Buyer Offering Plan will match the interests of potential buyers to the pharmacy with customized, focused marketing via PRS's extensive network of buyers and contacts.
In addition to the exclusive broker Seller/Buyer Offering Plan, PRS also is offering two non-exclusive wrap-around services that will assist NCPA members in the preparation, sale and transfer of a pharmacy business. PRS's Seller Prep Plan will ascertain a pharmacy's current operations and analyze how to make improvements that will normalize the potential selling price. Upon the sale of a pharmacy, PRS's Closing and Transfer Plan provides the expertise and support to plan and execute the transfer of the pharmacy.
Each PRS service is available separately or as a package.
FDA fast-tracks Genentech’s Rituxan
SOUTH SAN FRANCISCO, Calif. — The U.S. Food and Drug Administration granted Breakthrough Therapy Designation status to Genentech’s Rituxan, intended for the treatment of pemphigus vulgaris, a painful, disfiguring and potentially fatal autoimmune disease characterized by progressive blistering of skin and/or mucous membranes.
“I’m excited by the potential for Rituxan to serve as a much-needed, FDA-approved treatment option for patients who are currently faced with a treatment regimen that can cause significant, long-term side effects,” said Victoria P. Werth, M.D., professor of Dermatology and Medicine at the University of Pennsylvania.
This is the 15th Breakthrough Therapy Designation granted to Genentech since 2013. The FDA’s Breakthrough Therapy Designation, designed to expedite the development and review of medicines for serious diseases and help ensure patients have access to them as soon as possible, was granted based on data from a Phase II study. This study evaluated Rituxan plus oral corticosteroid treatment compared to corticosteroid as a first-line treatment in patients with moderate to severe PV.
Pemphigus vulgaris is an autoimmune, intraepidermal, blistering disease affecting the skin and mucous membranes. It is the most common type of a group of autoimmune disorders collectively called pemphigus. It is estimated that around three in every 100,000 people are diagnosed with this disease.